Q3 2023 Results - Reimagining Medicine

Company overview Innovation: Pipeline overview Cardiovascular Financial review Financial performance Immunology TNO155-SHP2 inhibitor NCT03114319 (CTNO155X2101) Solid tumors (single agent) Phase 1 Indication Phase Patients 255 Primary Outcome Measures Arms Intervention Target Patients Number of participants with adverse events Number of participants with dose limiting toxicities Drug: TNO155 Drug: TNO155 in combination with EGF816 (nazartinib) Adult patients with advanced solid tumors in selected indications Readout Milestone(s) 2024 Publication TBD Conclusions Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 76 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation